Lixte Biotech Hlds (LIXT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 5,107 | 1,039 | 4,204 | 5,353 | 4,824 |
| Other current assets | 0 | 0 | 78 | 147 | 150 |
| TOTAL | $5,178 | $1,146 | $4,309 | $5,561 | $5,093 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 7,555 | 0 | 0 | 0 | 0 |
| TOTAL | $7,555 | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $12,734 | $1,146 | $4,309 | $5,561 | $5,093 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 437 | 83 | 157 | 231 | 226 |
| Other current liabilities | 301 | 235 | 157 | 165 | 77 |
| TOTAL | $1,333 | $318 | $314 | $396 | $303 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 439 | 0 | 0 | 0 | 0 |
| TOTAL | $439 | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $1,772 | $318 | $314 | $396 | $303 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 11,618 | 2,684 | 2,249 | 1,666 | 1,375 |
| Common Shares | 1 | 0 | 0 | 0 | 1 |
| Retained earnings | -58,077 | -52,068 | -48,482 | -43,395 | -37,082 |
| Other shareholders' equity | 1,298 | 0 | 0 | 0 | 0 |
| TOTAL | $10,962 | $827 | $3,995 | $5,165 | $4,790 |
| Total Liabilities And Equity | $12,734 | $1,146 | $4,309 | $5,561 | $5,093 |